Geneva, 3 May 2021 – Gavi, the Vaccine Alliance announced today that it had signed an advance purchase agreement with Moderna for its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna). The agreement is for 500 million doses of the Moderna vaccine, secured on behalf of the COVAX Facility. Initial supply under the agreement is for AMC-eligible participants, with the potential to allocate and supply to self-financing participants in the future.
“We are very pleased to sign this new agreement with Moderna, giving COVAX Facility participants access to yet another highly efficacious vaccine,” said Dr Seth Berkley, CEO of Gavi. “Expanding and having a diverse portfolio has always been a core goal for COVAX, and to remain adaptable in the face of this continually evolving pandemic – including the rising threat posed by new variants. This agreement is a further step in that direction.”
The Moderna vaccine has recently received WHO Emergency Use Listing, making it eligible to be supplied to COVAX Facility participants. Supply via this APA is expected to commence in Q4 2021, with a total of 34 million doses available in 2021 and up to 466 million doses in 2022. The agreement also contains options to potentially access doses of variant-adapted vaccine in the future.
Moderna’s vaccine is part of the COVAX R&D portfolio. In January 2020, COVAX co-lead CEPI provided initial investment in Moderna’s COVID-19 vaccine programme to support production of the first clinical trial materials.
“CEPI’s early investment in Moderna’s vaccine development programme helped to get the project off the ground, so I’m proud that the vaccine will be made available to protect people in countries around the world through COVAX,” said CEPI CEO Dr Richard Hatchett. “This highly effective vaccine is already saving lives, and will play a vital role in the global control of COVID-19.”
“I am grateful to our COVAX partners for their tireless work and to the entire Moderna team for their collaboration to reach this agreement. This is an important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We recognize that many countries have limited resources to access COVID-19 vaccines. We support COVAX’s mission to ensure broad, affordable and equitable access to COVID-19 vaccines and we remain committed to doing everything that we can to ending this ongoing pandemic with our mRNA COVID-19 vaccine.”
Following on from the negotiation and signing of the APA between Gavi and Moderna, which secures these doses for the participants of the COVAX Facility, a long-term agreement will be signed between UNICEF and Moderna to enable to the logistics of procurement and delivery of these doses to Gavi COVAX AMC participants.
The announcement comes alongside news that Sweden plans to donate 1 million fully paid doses of the AstraZeneca(AZ)/Oxford vaccine to COVAX, responding to the call for countries to share doses urgently with COVAX to help address immediate-term supply delays. Doses shared in the short-term will help ensure AMC participants can administer second doses of the AZ/Oxford vaccine to high risk groups such as health care workers.